Supplies and Logistics

Malaria medicines

According to the recent estimates, there were about 219 million cases of malaria in 2010  and an estimated 660, 000 deaths. Malaria mortality rates have fallen by more than 25% globally since 2000  and by 33% in the WHO African Region. Most deaths occur among children living in Africa where a child dies every minute from malaria. Malaria is still a leading killer of children below the age of five.

Country-level burden estimates available for 2010 show that an estimated 80% of malaria deaths occur in just 14 countries and about 80% of cases occur in 17 countries.  Together, the Democratic Republic of the Congo and Nigeria account for over 40% of the estimated total of malaria deaths globally.

In high-burden settings, malaria can trap families and communities in a downward spiral of poverty, disproportionately affecting marginalized and poor people who cannot afford treatment or who have limited access to health care.

In response to widespread resistance of Plasmodium falciparum to monotherapy with conventional antimalarial medicines such as Chloroquine and sulfadoxine-pyrimethamine, World Health Organization (WHO) now recommends combination therapies as treatment policy for falciparum malaria in all countries experiencing such resistance. Artemisinin-based combination therapies (ACTs) are the most highly efficacious treatment regimens available. See WHO treatment guidelines.

The following ACTs are currently recommended by WHO in its Treatment Guidelines (alphabetical order):

• Artemether-Lumefantrine,
• Artesunate + Amodiaquine,
• Artesunate + Mefloquine,
• Artesunate + Sulfadoxine–Pyrimethamine.
•Dihydroartemisinin + piperaquine

Note: Amodiaquine + sulfadoxine–pyrimethamine may be considered as an interim option where ACTs cannot be made available, provided that efficacy of both is high
By 2011, 79 countries and territories had adopted ACTs as first-line treatment for P. falciparum malaria

UNICEF and WHO conduct a joint annual tender for antimalarial medicines based on current WHO malaria treatment guidelines. Wherever possible UNICEF will procure products prequalified by the WHO Prequalification Programme. Where no or limited number of prequalified products are available, UNICEF and WHO will carry out a detailed technical evaluation of other antimalarial products available in the global market, in cooperation with relevant partners and regulatory agencies.

In 2012, UNICEF procured 25 million antimalaria treatments (artemisinin-based combination therapy — ACTs) and 18 million rapid diagnostics tests (RDTs).

For more information on the malaria commodities available through UNICEF Supply Division, please visit the UNICEF supply catalogue
For more detailed information please contact the relevant persons for Malaria; the up-to-date contact details can be found on the WHO IS WHO pages

See more

WHO Global Malaria Programme:                    http://www.who.int/malaria/en/
WHO guidelines for the treatment of malaria:   http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html
WHO antimalarial treatment policy by region:   http://www.who.int/malaria/areas/treatment/drug_policies/en/index.html

 


 

 

UNICEF Supply Catalogue

New enhanced search